Vinorelbine ditartrate - CAS 125317-39-7
Catalog number: 125317-39-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C45H54N4O8.2C4H6O6
Molecular Weight:
1079.1
COA:
Inquire
Targets:
Microtubule/Tubulin | Others
Description:
Vinorelbine ditartrate, whose base is Vinorelbine, is a selective mitotic microtubule antagonist. It inhibits proliferation of Hela cells (IC50= 1.25 nM) and suppress microtubule dynamics (IC50 = 3.8 nM).
Brife Description:
Anti-mitotic agent; Inhibits proliferation of Hela cells (IC50= 1.25 nM); Suppress microtubule dynamics (IC50 = 3.8 nM)
Appearance:
White solid
Synonyms:
(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylic acid methyl ester; 125317-39-7; Navelbine; KW-2307; Ambap125317-39-7; MFCD03613607; AB15572; NVB; Q-100110; (2B,3B,4B,5A,12R,19A)-4-(ACETYLOXY)-6,7-DIDEHYDRO-15-[(2R,6R,8S)-4-ETHYL-1,3,6,7,8,9-HEXAHYDRO-8-(METHOXYCARBONYL)-2,6-METHANO-2H-AZECINO[4,3-B]INDOL-8-YL]-3-HYDROXY-16-METHOXY-1-METHYLASPIDOSPERMIDINE-3-CARBOXYLIC ACID; 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt]; 3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE [R-(R*,R*)-2-3-DIHYDROXYBUTANEDIOATE (1:2)SALT], 5'-NORANHYDRO; 3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE R-(R*,R*)-2-3-DIHYDROXYBUTANEDIOATE (1:2) SALT; 3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE R-(R*,R*)-2-3-DIHYDROXYBUTANEDIOATE SALT
Solubility:
Soluble to 100 mM in water and to 100 mM in DMSO
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -68℃ for long term (months to years).
MSDS:
Inquire
Melting Point:
181-183ºC
Density:
1.367 g/cm3
InChIKey:
CILBMBUYJCWATM-LNLXBTRNSA-N
InChI:
1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t28-,37+,38-,39-,42-,43-,44+,45+;2*1-,2-/m111/s1
Canonical SMILES:
CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O
1.Metastatic Angiosarcoma with Kasabach-Merritt Syndrome Responsive to Gemcitabine and Vinorelbine after Failure of Liposomal Doxorubicin and Paclitaxel: A Case Report.
Read WL1, Williams F1. Case Rep Oncol. 2016 Mar 12;9(1):177-81. doi: 10.1159/000444747.
Kasabach-Merritt syndrome (KMS) describes a consumptive coagulopathy associated with certain vascular tumors. It is thought that platelets are destroyed as they circulate through the aberrant endothelial surfaces associated with these tumors. Most published literature describes infants with kaposiform hemangioendothelioma, but a similar syndrome can complicate angiosarcoma in adults. This report describes a man with metastatic angiosarcoma arising in the scalp in whom disease progression was complicated by profound thrombocytopenia consistent with KMS. His disease and associated KMS had progressed previously through paclitaxel and then through liposomal doxorubicin. It did not respond to paclitaxel and bevacizumab, but responded almost completely to chemotherapy with gemcitabine and vinorelbine. Six months later, progression through ongoing chemotherapy then responded to chemotherapy with cyclophosphamide and sirolimus.
2.A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.
Elharrar X1,2, Barbolosi D3, Ciccolini J3, Meille C3, Faivre C3, Lacarelle B3, André N3,4,5, Barlesi F6,7,8. BMC Cancer. 2016 Apr 20;16(1):278. doi: 10.1186/s12885-016-2308-z.
BACKGROUND: Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. Mathematical modelling showed by simulation that a new metronomic protocol could lead to a better safety and efficacy profile.
3.Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F1,2,3, Kattan JG4,5, Ghosn M4,5. Cancer Chemother Pharmacol. 2016 May;77(5):1069-77. doi: 10.1007/s00280-016-3027-5. Epub 2016 Apr 8.
PURPOSE: Vinorelbine-trastuzumab combination proved to be an effective first-line treatment for patients with locally advanced or metastatic breast cancer (MBC). Oral chemotherapy represents a step forward in MBC management. To improve patients' comfort using the oral form of vinorelbine, we conducted a multicenter phase II study to investigate the efficacy and safety of the oral vinorelbine-trastuzumab combination in women with MBC with human epidermal growth factor receptor 2 (HER2) overexpression.
4.Multifunctional targeting vinorelbine plus tetrandrine liposomes for treating brain glioma along with eliminating glioma stem cells.
Li XT1, Tang W2, Jiang Y1, Wang XM1, Wang YH1, Cheng L1, Meng XS1. Oncotarget. 2016 Mar 25. doi: 10.18632/oncotarget.8360. [Epub ahead of print]
Malignant brain glioma is the most lethal and aggressive type of cancer. Surgery and radiotherapy cannot eliminate all glioma stem cells (GSCs) and blood-brain barrier (BBB) restricts the movement of antitumor drugs from blood to brain, thus leading to the poor prognosis with high recurrence rate. In the present study, the targeting conjugates of cholesterol polyethylene glycol polyethylenimine (CHOL-PEG2000-PEI) and D-a-tocopheryl polyethylene glycol 1000 succinate vapreotide (TPGS1000-VAP) were newly synthesized for transporting drugs across the BBB and targeting glioma cells and GSCs. The multifunctional targeting vinorelbine plus tetrandrine liposomes were constructed by modifying the targeting conjugates. The studies were undertaken on BBB model, glioma cells, GSCs, and glioma-bearing mice. In vitro results showed that multifunctional targeting drugs-loaded liposomes with suitable physicochemical property could enhance the transport drugs across the BBB, increase the intracellular uptake, inhibit glioma cells and GSCs, penetrate and destruct the GSCs spheroids, and induce apoptosis via activating related apoptotic proteins.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products


CAS 90332-66-4 7-xylosyltaxol

7-xylosyltaxol
(CAS: 90332-66-4)

7-xylosyltaxol is a taxol (Paclitaxel) derivative, which binds to tubulin and inhibits the disassembly of microtubules.

RO 5263397
(CAS: 1357266-05-7)

RO5263397 is a selective trace amine-associated receptor 1(TAAR1) agonist. TAAR1 is a drug discovery target for cocaine addiction. RO5263397 is efficacious in r...

CAS 125-69-9 Dextromethorphan hydrobromide

Dextromethorphan hydrobromide
(CAS: 125-69-9)

Non-competitive, low affinity NMDA receptor antagonist. Displays antitussive and neuroprotective effects. Active in vivo.

CAS 162652-95-1 Vinflunine

Vinflunine
(CAS: 162652-95-1)

Vinflunine is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity.

CAS 51-79-6 Urethane

Urethane
(CAS: 51-79-6)

Urethane is an ester of carbamic acid used as an antineoplastic agent and for other medicinal purposes.

CAS 880813-36-5 PhiKan 083

PhiKan 083
(CAS: 880813-36-5)

PhiKan 083 is a critical p53 stabilizing agent by bonding its mutation Y220C.

CAS 117048-59-6 Combretastatin A4

Combretastatin A4
(CAS: 117048-59-6)

Combretastatin A4, under the IUPAC name 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, inhibits tubulin polymerization (IC50= 2.2 μM). It has demons...

ACI-35

ACI-35 is a liposome-based vaccine designed to stimulate a patient’s immune system to produce antibodies against the misfolded and phosphorylated pathogenic for...

Chemical Structure

CAS 125317-39-7 Vinorelbine ditartrate

Quick Inquiry

Verification code

Featured Items